Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

STRATA Skin Sciences (SSKN) EBITDA (2016 - 2025)

Historic EBITDA for STRATA Skin Sciences (SSKN) over the last 13 years, with Q3 2025 value amounting to -$1.2 million.

  • STRATA Skin Sciences' EBITDA rose 2691.59% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.7 million, marking a year-over-year decrease of 1515.26%. This contributed to the annual value of -$9.3 million for FY2024, which is 756.62% down from last year.
  • Latest data reveals that STRATA Skin Sciences reported EBITDA of -$1.2 million as of Q3 2025, which was up 2691.59% from -$2.2 million recorded in Q2 2025.
  • STRATA Skin Sciences' EBITDA's 5-year high stood at $134000.0 during Q4 2022, with a 5-year trough of -$4.3 million in Q4 2024.
  • Moreover, its 5-year median value for EBITDA was -$1.7 million (2022), whereas its average is -$1.7 million.
  • In the last 5 years, STRATA Skin Sciences' EBITDA skyrocketed by 12154.34% in 2022 and then crashed by 266791.04% in 2023.
  • STRATA Skin Sciences' EBITDA (Quarter) stood at -$622000.0 in 2021, then surged by 121.54% to $134000.0 in 2022, then crashed by 2667.91% to -$3.4 million in 2023, then dropped by 24.53% to -$4.3 million in 2024, then skyrocketed by 72.63% to -$1.2 million in 2025.
  • Its EBITDA stands at -$1.2 million for Q3 2025, versus -$2.2 million for Q2 2025 and -$2.0 million for Q1 2025.